Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr;30(2):204-208.
doi: 10.1097/MOP.0000000000000592.

Neonatal hypoglycemia: continuous glucose monitoring

Rajesh Shah  1 , Christopher J D McKinlay  1   2   3 , Jane E Harding  1
Affiliations
Review

Neonatal hypoglycemia: continuous glucose monitoring

Rajesh Shah et al. Curr Opin Pediatr. 2018 Apr.

Abstract

Purpose of review: Continuous glucose monitoring (CGM) is increasingly used in the management of diabetes in children and adults, but there are few data regarding its use in neonates. The purpose of this article is to discuss the potential benefits and limitations of CGM in neonates.

Recent findings: Smaller electrodes in new sensors and real-time monitoring have made CGM devices more approachable for neonatal care. CGM is well tolerated in infants including very low birth weight babies, and few if any local complications have been reported. Use of CGM in newborns may reduce the frequency of blood sampling and improve glycemic stability, with more time spent in the euglycemic range. However, CGM may also lead to more intervention, with potential adverse effects on outcomes. More information is also needed about reliability, calibration and interpretation of CGM in the neonate.

Summary: Although the use of CGM in neonates appears to be well tolerated, feasible and has been associated with better glycemic status, there is not yet any evidence of improved clinical outcomes. Clinical utility of CGM should be demonstrated in randomized trials prior to its introduction into regular neonatal care.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

None

References

    1. McGarraugh G. The chemistry of commercial continuous glucose monitors. Diabetes Technol Ther. 2009;11(S1):S17–24. - PubMed
    1. McKinlay CJD, Chase JG, Dickson J, et al. Continuous glucose monitoring in neonates: a review. Matern Health Neonatol Perinatol. 2017;3(1):18. A review of CGMS including the biomedical engineering aspects of CGM, calibration issues, and use in neonates. - PMC - PubMed
    1. Stechova K, Cerny M, Brabec R, et al. Experience with real time continuous glucose monitoring in stabilising fluctuating glycaemia during intensive care of the preterm infant of a diabetic mother. J Matern Fetal Neonatal Med. 2014;27(13):1389–91. - PubMed
    1. Tiberi E, Cota F, Barone G, et al. Continuous glucose monitoring in preterm infants: evaluation by a modified Clarke error grid. Ital J Pediatr. 2016;42(1):29. A non-randomized study on feasibility and reliability of CGM in preterm infants. - PMC - PubMed
    1. Uettwiller F, Chemin A, Bonnemaison E, et al. Real-time continuous glucose monitoring reduces the duration of hypoglycemia episodes: a randomized trial in very low birth weight neonates. PLoS One. 2015;10(1):e0116255. A randomized trial in very low birth weight infants of CGM versus intermittent capillary glucose measurement for detection and management of hypoglycemia. - PMC - PubMed

Publication types